Retrospective Cohort Study
Copyright ©The Author(s) 2024.
World J Gastroenterol. Apr 7, 2024; 30(13): 1859-1870
Published online Apr 7, 2024. doi: 10.3748/wjg.v30.i13.1859
Table 1 Baseline characteristics of the study cohort, n (%)
Variable
Variable
SexNone151 (38.4)
Male278 (70.7)Small138 (35.1)
Female115 (29.3)Moderate to large104 (26.5)
Age (yr)Pre-HE
< 60307 (78.1)No387 (98.5)
≥ 6086 (21.9)Yes6 (1.5)
Etiology of cirrhosisSBP
Hepatitis B virus254 (64.6)Yes106 (27.0)
Hepatitis C virus16 (4.1)No287 (73.0)
Alcoholic35 (8.9)Type of stent
Autoimmune40 (10.2)Composite stent1265 (67.2)
Others48 (12.2)Viatorr® stent128 (32.6)
DiabetesPre-PVP (mmH2O)
Yes67 (17.0)> 33.9305 (77.6)
No326 (83.0)≤ 33.988 (22.4)
HypertensionPost-PVP (mmH2O)
Yes27 (6.9)> 23.1295 (75.1)
No366 (93.1)≤ 23.198 (24.9)
Indications for TIPSK (mmol/L)
Variceal bleeding357 (90.8)< 3.595 (24.2)
Refractory ascites36 (9.2)3.5-5.5295 (75.1)
Formation of PVT> 5.33 (0.8)
Yes94 (23.9)Na (mmol/L)
No299 (76.1)< 137124 (31.6)
Endoscopic treatment history≥ 137269 (68.4)
Yes115 (29.3)BUN (mmol/L)
No278 (70.7)< 3.128 (7.1)
Splenectomy history≥ 3.1365 (92.9)
Yes15 (3.8)SCr (μmol/L)
No378 (96.2)≤ 106356 (90.6)
Ascites> 10637 (9.4)
ALB (g/L)PT (s)
< 40330 (84.0)≤ 14.554 (13.7)
≥ 4063 (16.0)> 14.5339 (86.3)
ALT (U/L)352 (88.0)FIB (g/L)
≤ 50350 (89.1)< 2216 (55.0)
> 5043 (10.9)≥ 2177 (45.0)
AST (U/L)Hb (g/L)
≤ 40279 (71.0)< 130328 (83.5)
> 40114 (29.0)≥ 13065 (16.5)
ALP (U/L)WBC (109/L)
≤ 135342 (87.0)< 3.5236 (60.1)
> 13551 (13)3.5-9.5144 (36.6)
GGT (U/L)> 9.513 (3.3)
≤ 60295 (75.1)PLT (109/L)
> 6098 (24.9)< 125322 (81.9)
TBIL (μmol/L)≥ 12571 (18.1)
≤ 28301 (76.6)Child-Pugh grade
> 2892 (23.4)A169 (43.0)
PA (mg/L)B185 (47.1)
< 150321 (81.7)C39 (9.9)
≥ 15072 (18.3)MELD score
INRLow risk354 (90.1)
≤ 1.3190 (48.3)Medium risk31 (7.9)
> 1.3203 (51.7)High risk8 (2.0)